Provided by Tiger Trade Technology Pte. Ltd.

Alvotech

5.31
+0.06501.24%
Volume:261.90K
Turnover:1.39M
Market Cap:1.89B
PE:-8.72
High:5.39
Open:5.28
Low:5.26
Close:5.24
52wk High:9.25
52wk Low:2.94
Shares:357.00M
Float Shares:141.00M
Volume Ratio:1.42
T/O Rate:0.19%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6081
EPS(LYR):0.0964
ROE:--
ROA:2.19%
PB:-9.89
PE(LYR):55.05

Loading ...

Regeneron Pharmaceuticals More Likely to Retain Eylea HD Patent, RBC Says

MT Newswires Live
·
Yesterday

Sector Update: Healthcare Stocks Decline Monday Afternoon

MT Newswires Live
·
Sep 01

Alvotech Stock Gains After FDA Accepts for Review Crohn's Treatment AVT80

Dow Jones
·
Sep 01

Alvotech Says FDA Accepts AVT80 Biosimilar Application for Review

Reuters
·
Aug 31

Alvotech Announces FDA Acceptance for Review of Biologics License Application for Avt80, Expanding Proposed Biosimilar Program for Entyvio® to Subcutaneous Presentations

THOMSON REUTERS
·
Aug 31

Alvotech Executives to Speak at Morgan Stanley Global Healthcare Conference Fireside Chat

Reuters
·
Aug 27

Alvotech to present at upcoming investor conferences in September

GlobeNewswire
·
Aug 27

Alvotech's Q4 Approval, Launch Timelines Remain Intact, UBS Says

MT Newswires Live
·
Aug 25

Alvotech Sa : Bofa Global Research Initiates Coverage with Buy Rating; Price Objective $7

THOMSON REUTERS
·
Aug 24

BofA Securities Initiates Alvotech at Buy With $7 Price Target

MT Newswires Live
·
Aug 24

Lotus Pharma Unit to License Two Alvotech Biosimilars in $150 Million Deal

MT Newswires Live
·
Aug 24

Alvotech Strikes $150 Million Biosimilar Deal With Lotus for U.S. and Key Asian Markets

TIPRANKS
·
Aug 21

Alvotech Signs Licensing, Commercialization Deal with Lotus Pharma for Imfinzi, Hemlibra Biosimilars in US, Asia

Reuters
·
Aug 21

Alvotech - Announces Strategic Licensing and Commercialization Agreement with Lotus Pharmaceutical

THOMSON REUTERS
·
Aug 21

Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for Proposed Biosimilars to Durvalumab and Emicizumab in the U.S. and Selected Asian Markets

THOMSON REUTERS
·
Aug 21

Alvotech - Retains Right to Commercialize Avt34 and Avt87 Directly in U.S.

THOMSON REUTERS
·
Aug 21

Alvotech - Lotus Granted Exclusive Rights for Avt34 and Avt87 in Eight Asian Markets

THOMSON REUTERS
·
Aug 21

Alvotech - Agreement Has Potential Value of up to $150 Mln in Upfront and Milestone Payments

THOMSON REUTERS
·
Aug 21

Analysts Offer Insights on Healthcare Companies: Corcept Therapeutics (CORT), Alvotech (ALVO) and Abbott Laboratories (ABT)

TIPRANKS
·
Aug 21

Iceland's Alvotech H1 Revenue Falls 31% on Manufacturing Program

Reuters
·
Aug 20